Glucose concentration monitoring using a small Fabry-Perot etalon.

Accurate measurements of aqueous glucose concentrations have been made in a double-chamber Fabry-Perot etalon that can be miniaturized for subcutaneous implantation to determine the concentration of glucose in interstitial fluid. In general, optical approaches to glucose detection measure light intensity, which in tissue varies due to inherent scattering and absorption. In our measurements, we compare the spectral positions of transmission maximums in two adjunct sections of an etalon in order to determine the refractive index difference between these sections and therefore we can tolerate large changes in intensity. With this approach, we were able to determine aqueous glucose concentrations between 0 mg/dl and 700 mg/dl within the precision of our reference measurement (+/-2.5 mg/dl or 2% of the measurement value). The use of reference cavities eliminates interference due to temperature variations, and we show the temperature independence over a temperature range of 32 degrees C to 42 degrees C. Furthermore, external filters eliminate interference from large molecule contaminants.

[1]  K Zirk,et al.  On the suitability of refractometry for the analysis of glucose in blood-derived fluids. , 2004, Medical engineering & physics.

[2]  A. Boiarski,et al.  Diffusion characteristics of microfabricated silicon nanopore membranes as immunoisolation membranes for use in cellular therapeutics. , 2005, Diabetes technology & therapeutics.

[3]  D. Cox,et al.  Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose , 1987, Diabetes Care.

[4]  W Kenneth Ward,et al.  Vascularizing the tissue surrounding a model biosensor: how localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF)? , 2003, Biosensors & bioelectronics.

[5]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[6]  O. Khalil,et al.  Spectroscopic and clinical aspects of noninvasive glucose measurements. , 1999, Clinical chemistry.

[7]  Robert Puers,et al.  An inductive power system with integrated bi-directional data-transmission , 2004 .

[8]  I. Goldstein,et al.  Protein-carbohydrate interaction. VI. Isolation of concanavalin A by specific adsorption on cross-linked dextran gels. , 1967, Biochimica et biophysica acta.

[9]  Michael O'Grady,et al.  Continuous glucose monitoring and intensive treatment of type 1 diabetes. , 2008, The New England journal of medicine.

[10]  H. Murphy,et al.  Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial , 2008, BMJ : British Medical Journal.

[11]  Francis Moussy,et al.  A novel porous collagen scaffold around an implantable biosensor for improving biocompatibility. I. In vitro/in vivo stability of the scaffold and in vitro sensitivity of the glucose sensor with scaffold. , 2008, Journal of biomedical materials research. Part A.

[12]  Bettina Petersen,et al.  Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. , 2007, Diabetes technology & therapeutics.

[13]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[14]  Francis Moussy,et al.  Use of hydrogel coating to improve the performance of implanted glucose sensors. , 2008, Biosensors & bioelectronics.

[15]  G. Steil,et al.  Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. , 1999, The American journal of physiology.

[16]  G L Coté,et al.  Noninvasive and minimally-invasive optical monitoring technologies. , 2001, The Journal of nutrition.

[17]  G. Edelman,et al.  Binding and functional properties of concanavalin A and its derivatives. I. Monovalent, divalent, and tetravalent derivatives stable at physiological pH. , 1978, The Journal of biological chemistry.

[18]  F. Ovalle,et al.  Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes , 2009 .

[19]  G. Rao,et al.  Transport properties of pHEMA membranes for optical glucose affinity sensors , 2003 .

[20]  Manfred Berroth,et al.  Tunable liquid crystal Fabry-Perot filters , 2003, Photonics Fabrication Europe.

[21]  R J McNichols,et al.  Optical glucose sensing in biological fluids: an overview. , 2000, Journal of biomedical optics.

[22]  P. Cryer,et al.  Hypoglycemia in diabetes. , 2003, Diabetes care.

[23]  S. Garg,et al.  Use of continuous glucose monitoring in patients with type 1 diabetes. , 2008, Current diabetes reviews.

[24]  I. Goldstein,et al.  Specific binding of concanavalin A to cross-linked dextran gels. , 1965, The Biochemical journal.

[25]  Graham Ramsay,et al.  Commercial biosensors : applications to clinical, bioprocess, and environmental samples , 1998 .

[26]  D. Dorsky,et al.  Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization. , 2005, Biomaterials.

[27]  Kai Zirk,et al.  A refractometry-based glucose analysis of body fluids. , 2007, Medical engineering & physics.

[28]  E Wilkins,et al.  Glucose monitoring: state of the art and future possibilities. , 1996, Medical engineering & physics.

[29]  J. Schultz,et al.  A fluorescence affinity hollow fiber sensor for continuous transdermal glucose monitoring. , 2000, Analytical chemistry.

[30]  V. R. Kondepati,et al.  Recent progress in analytical instrumentation for glycemic control in diabetic and critically ill patients , 2007, Analytical and bioanalytical chemistry.

[31]  F Moussy,et al.  In vitro and in vivo degradation of glucose oxidase enzyme used for an implantable glucose biosensor. , 2000, Diabetes technology & therapeutics.

[32]  A. Maran,et al.  Non-invasive glucose monitoring: assessment of technologies and devices according to quantitative criteria. , 2007, Diabetes research and clinical practice.